Abstract: The invention provides cDNAs which encodes a signal peptide-containing proteins. It also provides for the use of a cDNA, protein, and antibody in the diagnosis, prognosis, treatment and evaluation of therapies for cancer. The invention further provides vectors and host cells for the production of the protein and transgenic model systems.

Abstract: Novel bacteriocins produced by novel bacterial strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry.

Abstract: The present invention relates to enzymes from the cytochrome P450 family and to the nucleotide sequences encoding them, and to their use in a method for the generation of pathogen-resistant plants.

Abstract: Framework (FR)-patching is a novel approach to modify immunoglobulin for reducing potential immunogenicity without significant alterations in specificity and affinity. Unlike previous described methods of humanization, which graft CDRs from a donor onto the frameworks of a single acceptor immunoglobulin, we patch segments of framework (FR1, FR2, FR3, and FR4), or FRs, to replace the corresponding FRs of the parent immunoglobulin. Free assortment of these FRs from different immunoglobulins and from different species can be mixed and matched into forming the final immunoglobulin chain. A set of criteria in the choice of these FRs to minimize or eliminate the need to reintroduce framework amino acids from the parent immunoglobulin for patching is described. The approach gives greater flexibility in the choice of framework sequences, minimizes the need to include parent framework amino acids, and, most importantly, reduces the chances of creating new T- and B-cell epitopes in the resultant immunoglobulin.

Abstract: The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tumors, e.g., carcinomas, melanomas and other tumors. In another embodiment, the invention relates to methods of imaging tumors using radiolabeled metal complexes. Preferred radiolabeled complexes for imaging tumors include technetium and rhenium complexes. The high tumor uptake and significant tumor/nontumor ratios of the technetium complexes of the invention indicate that such small technetium-99m-based molecular probes can be developed as in-vivo diagnostic agents for melanoma and its metastases. In yet another embodiment, the invention relates to methods of treatment of tumors using a radiolabeled metal complex as a radiopharmaceutical agent to treat the tumor.

Abstract: Novel NBS-1 or PYRIN-1 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated NBS-1 or PYRIN-1 proteins, the invention further provides NBS-1 or PYRIN-1 fusion proteins, antigenic peptides and anti-NBS-1 or anti-PYRIN-1 antibodies. The invention also provides NBS-1 or PYRIN-1 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a NBS-1 or PYRIN-1 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one 2?-arabino-fluoronucleoside and an internucleoside 3?-NH—P(—O)(OR)—O-5? linkage, where R is a positively charged counter ion or hydrogen, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive phosphoramidate 2?-arabino-fluorooligonucleotides have a high RNA binding affinity to complementary nucleic acids and are base and acid stable.

Abstract: A promoter domain of 1816 bp or 441 bp in the upstream side of exon 1B of IAI.3B gene has a specifically high promoter activity in ovarian cancer cells. An adenovirus having this promoter domain inserted in the E1 domain thereof exhibits a specifically high cell proliferation inhibitory effect on ovarian cancer cells. Thus, it is efficacious in gene therapy for ovarian cancer.

Abstract: The present invention provides compositions for regulating expression of isolated nucleotide sequences in a plant. The compositions are novel nucleic acid sequences for seed-preferred regulatory sequences.

Abstract: PCR primers for detecting Bifidobacterium infantis comprising: a pair of a first oligonucleotide having a sequence of 20 or more continuous nucleotides selected from a nucleotide sequence of SEQ ID NO: 1 and a second oligonucleotide having a nucleotide sequence of SEQ ID NO: 2 or a nucleotide sequence of SEQ ID NO: 2 in which 0 to 7 nucleotides has been deleted from its 5?-terminal side is used to perform PCR using a chromosomal DNA or 16S rRNA of test bacteria as a template, and whether an amplicon of Bifidobacterium infantis is present or not is determined.

Abstract: The invention is directed to 3-?-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.

Abstract: The invention relates to a process for the depolymerization of glycosaminoglycanes characterized by the use of electron beam radiation, optionally in the presence of an organic compound selected from the group consisting of ethers, alcohols, aldehydes, amides and formic acid. The invention also relates to the intermediate depolymerized heparin obtained by the process. The intermediate depolymerized heparin can be dissolved in a buffer solution and fractionated by gel permeation for obtaining the desired molecular weight.

Abstract: A process for conveniently and efficiently preparing a 2,6-dihalogenopurine using an inexpensive starting material. A process for preparing a 2,6-dihalogenopurine, comprising treating a 2-amino-6-halogenopurine having a protective group at 7th position or 9th position with a diazotizating agent and a halogen source; and a process for preparing a 9-acyl-2-amino-6-halogenopurine, comprising treating a 2-amino-6-halogenopurine with an acylating agent in the presence of a base.

Abstract: A process for forming the facial isomer of an aluminum trisquinoline complex comprises heating the solid aluminum trisquinoline complex material at a temperature at least 50° C. below the melting point temperature of the solid for a time sufficient to convert the aluminum trisquinoline complex to at least 99 mol % of one polymorph of the facial-isomer that fluoresces with a maximum intensity below 510 nm.

Abstract: A photosensitizer dye is provided. The photosensitizer dye contains a Ru complex represented by the following formula (1): wherein Y1 and Y2 independently represent hydrogen atom (H), lithium (Li), sodium (Na) or tetra-alkyl ammonium groups (as represented by the following general formula (2)). wherein A, B, C and D independently represents CmH2m+1 (m=1˜6).

Abstract: A method for the catalytic conversion of codeine, morphine or analogs thereof into hydrocodone, hydromorphone or analogs thereof utilizing a transition metal catalyst of the formula [M(PR3R4R5)nXm]p; wherein R1 is H, alkyl, aryl or acyl; M is a Group VIII transition metal; R3, R4 and R5 are selected from the group consisting of alkyl, aryl, alkoxyl, phenoxyl and combinations thereof; X is a halide or an anion; n is 1, 2, 3 or 4; m is 1 or 2; and p is at least 1.

Abstract: The invention relates to a new industrially useable process for preparing tropenol, optionally in the form of the acid addition salts thereof.

Abstract: The present invention relates to novel triazolo-pyridines of the formula wherein X is >CH2, >NH, sulfur, >S?O, >SO2 or oxygen; wherein said >CH2 and >NH may optionally be substituted with a suitable substituent; R1 is selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents; R2 is selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents; s is an integer from 0-4; R3 is R4, R5—(NR6)—, R5—S—, R5—(S?O)—, R5—(SO2)—, R5—SO2—NR6—, R5—(NR6)—SO2—, R5—O—, R5—(C?O)—, R5—(NR6)—(C?O)—, R5—(C?O)—NR6—, R5—O—(C?O)—, R5—(C?O)—O—, R5—CR7?CR8— or R5—C?C—; such that the molecular weight of R3 is less than 500 AMU, preferably less than 250 AMU; R4, R5 and R6 are each selected from the group consisting of hydrogen, (C1-C6)alkyl and other suitable substituents; or a pharmaceutically acceptable salt thereof; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use.

Abstract: Disclosed are compounds of formula (I): wherein R3, R5, R7 and R8 are defined herein, which are useful as inhibitors SYK kinase and are thus useful for treating diseases resulting from inappropriate mast cell activation, which include allergic and inflammatory diseases. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

Abstract: The invention relates to a process for preparing N-substituted 3?-aminonortropanes of formula I wherein R1 has the meaning given in the claims, from the corresponding 3-oxonortropane or the corresponding 3?-aminonortropane, in which the latter is converted with an arylmethylamine or an arylaldehyde into the corresponding imines which are then tautomerised or isomerised and then hydrolysed. The invention also relates to the new compounds of formula V wherein R1 and Ar have the meanings given in the claims.

Abstract: Disclosed herein is a process for the preparation of a compound of the formula (II): or a salt thereof, wherein X is halogen; each Y, which may be the same or different, is halogen, haloalkyl, alkoxycarbonyl or alkylsulphonyl, and n is 0 to 3; which process comprises treating a compound of the formula (III): with a cyanide source and a catalyst selected from the group consisting of a tetraalkyl ammonium salt and a tetraalkyl phosphonium salt in an aqueous solvent or without solvent, wherein: X is halogen; each Y, which may be the same or different, is halogen, haloalkyl, alkoxycarbonyl or alkylsulphonyl: and n is 0 to 3; and wherein the cyanide source is hydrogen cyanide, an alkali metal cyanide, an alkaline earth metal cyanide or an optionally substituted ammonium cyanide.

Abstract: The invention relates to intermediate products and a new process for the production of benzocycloheptene C. The process for the production of its new intermediate products according to the invention starts from economical starting materials, provides the intermediate stages in high yields and high purity, without chromatographic purification steps, and allows production on an industrial scale.

Abstract: The present invention describes novel compounds of the formula: (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.

Abstract: Dictyostatin and its analogs show great promise as new anticancer agents. The present invention provides dictyostatin analogs, synthetic intermediates for the synthesis of dictyostatin analogs, and synthetic methods for the synthesis of such analogs and intermediates.

Abstract: An individual tetrahydrocannabinol isomer of interest is separated from a mixture containing two or more such isomers, by treating the mixture with an isocyanate or isothiocyanate of formula I: R—(CH2)n—N?C?X??(I) where R represents an aromatic ring optionally substituted with one or more electron withdrawing groups, n=0 or 1 and X is oxygen or sulphur; so as to produce a crystallizable THC carbamate of formula II: wherein X and R are as defined above, R? is a C3-C10 alkyl group and the dotted lines indicate optional unsaturation including aromatic, separating the compound of formula II from solution in isolation of other THC derivatives, and hydrolyzing the compound of formula II to form the individual tetrahydrocannabinol isomer of interest.

Abstract: A method of purifying an organometallic compound by heating the organometallic compound in the presence of a trialkyl aluminum compound and a catalyst.

Abstract: The present invention is directed to labeled compounds of the formulae wherein Q is selected from the group consisting of —S—, —S(?O)—, and —S(?O)2—, Z is selected from the group consisting of 1-naphthyl, substituted 1-naphthyl, 2-naphthyl, substituted 2-naphthyl, and phenyl groups with the structure wherein R1, R2, R3, R4 and R5 are each independently selected from the group consisting of hydrogen, a C1-C4 lower alkyl, a halogen, and an amino group selected from the group consisting of NH2, NHR and NRR? where R and R? are each independently selected from the group consisting of a C1-C4 lower alkyl, an aryl, and an alkoxy group, and X is selected from the group consisting of hydrogen, a C1-C4 lower alkyl group, and a fully-deuterated C1-C4 lower alkyl group. The present invention is also directed to a process of preparing labeled compounds, e.g.

Abstract: The present invention provides novel diphenyl ethene compounds and pharmaceutically-acceptable salts thereof. Also provided are methods for making the compounds of the invention as well as methods for the use thereof in the treatment of immune, inflammatory, and auto-immune diseases.

Abstract: It is an object of the present invention to provide a vinyl ether group-containing (meth)acrylic ester, which has both radical polymerizability and cation polymerizability, improved in storage stability and stability in handling without impairing its polymerizability or, in other words, provide a stabilized vinyl ether group-containing (meth)acrylic ester. Another object is to provide a method of producing a stabilized vinyl ether group-containing (meth)acrylic ester composition. A further object is to provide a method of stably handing, a method of economically and stably producing and a method of purifying a vinyl ether group-containing (meth)acrylic ester.

Abstract: A process for the preparation of a fuel oil (diesel fuel or heating oil) composition which is a mixture of an alkanol tranesterified fatty acid ester triglyceride and an acetal of glycerol is described. The process preferably provides a prestep of the formation of at least some of the alkanol transesterified triglyceride containing the glycerol for use in the formation of the acetal of glycerol. The composition can also be formed from a reaction of 1,1-dimethoxy- or 1,1-diethoxyethane and glycerol to form the acetal in the alkanol transesterified triglyceride.

Abstract: A process for the manufacture of a tocyl acylate or a tocopheryl acylate comprises reacting tocol or a tocopherol with an acylating agent in the presence of a solid heterogeneous Brönsted acid catalyst, said catalyst being an inorganic Brönsted acid on a solid carrier material which comprises silicon dioxide, titanium dioxide or both silicon dioxide and titanium dioxide, or being an organofunctional polysilonaxe featuring sulpho groups, the solid heterogeneous Brönsted acid catalyst further featuring a BET surface area from about 10 m2/g to about 800 m2/g and a pore volume from about 0.1 ml/g to about 2.0 ml/g. The main commercial form of vitamin E, being (all-rac)-?-tocopheryl acetate, can be manufactured by acylation of (all-rac)-?-tocopherol according to this process.

Abstract: Poly(ortho-methylphenol) is obtainable at high purities and yields using industrial processes by causing a secondary amine and formaldehyde to react with a polyphenol (first step), and then breaking down the aminomethyl group of the obtained poly(ortho-aminomethyl)phenol by means of hydrogenolysis in the presence of a hydrogenation catalyst (second step).

Abstract: Optically active diphenylalanine compounds may be conveniently prepared in a good yield by reacting a diphenylalanine compound represented by formula (1) with an optically active amine compound represented by formula (2) in the presence of an organic solvent to give a diastereomeric salt represented by formula (5) and then treating the diastereomeric salt under acidic conditions to give an optically active diphenylalanine compound represented by formula (3): wherein each symbol is as defined in the specification.

Abstract: The present invention is directed to a novel compound, its composition and use of a compound having a structural formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomers thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases

Abstract: The present invention provides a new method for manufacturing a prostaglandin analogue having one or more keto groups on the 5-membered ring and/or omega chain, which comprises the step of treating a corresponding hydroxyl group containing compound with a co-oxidizer under the presence of a tetramethylpyperidine-1-oxyl derivative to form the desired prostaglandin analogue. The method of the invention can be carried out easily under relatively mild conditions.

Abstract: Acrolein and/or acrylic acid are prepared from propane and/or propene by a process comprising the following steps: (a) separation of propane and/or propene from a propane- and/or propene-containing gas mixture by absorption in an absorbent, (b) separation of the propane and/or propene from the absorbent to give a gas B and (c) use of the gas B obtained in stage (b) for an oxidation of propane and/or propene to acrolein and/or acrylic acid, no heterogeneously catalyzed dehydrogenation of propane without supply of oxygen being carried out between steps (b) and (c).

Abstract: Compounds of formula (I): or salts or solvate thereof, wherein: n and N independently represent an integer 2 to 12; m1 and m2 independently represent an integer 1 to 15; and R1 and R2 independently represent —(CO)xC1-9 alkyl or —(CO)xC1-9 fluoroalkyl, which fluoroalkyl moiety contains at least 1 fluorine atom and not more than 3 consecutive perfluorocarbon atoms wherein x represents 0 or 1, as well as pharmaceutical formulations containing such compounds and processes for the manufacture of such compounds are disclosed. Intermediates of such compounds and processes for the manufacture of such intermediates are also disclosed.

Abstract: A method for the production of acrylic acid of high concentration by absorbing acrylic acid with high absorption ratio of acrylic acid is provided. In a method for producing acrylic acid by a procedure comprising a step of catalytic gas phase oxidation reaction and a step of absorbing the acrylic acid-containing gas, while a low boiling substance-containing solution is introduced into the absorption column via a portion different from the top of the column.

Abstract: The present invention provides processes for the preparation of arylalkylsulfonyl halides and heteroarylalkylsufonyl halides of Formula I: Ar—R—SO2—X, that are useful as intermediates in the preparation of pharmaceuticals.

Abstract: A process for the synthesis of (per)fluorinated mono-functional carbonyl compounds having the following formula: F—A—(RF)t—B—C(O)X1??(I) wherein: X1=F, CF3; t=0, 1; A, B equal to or different from each other, are independently C1-C5 (per)fluoroalkylene groups or C1-C5 (per)fluorooxy-alkylene groups; RF is —Rf1—, C1-C20 perfluoroalkylene, —ORf1O—; or —ORf2—, wherein Rf2 is a perfluorooxyalkylene chain; wherein the carbonyl groups of a (per)fluorinated di-functional carbonyl compound of formula (III): X2(O)C—A—(RF)t—B—C(O)X1??(III) wherein: X1, RF, t, A and B have the above meanings; X2, equal to or different from X1, has the same meanings as X1; are partially fluorinated with elemental fluorine in the presence of a catalyst having formula MeFy.zHF, Me being an alkaline or alkaline-earth metal or Ag, y=1 or 2, z an integer from 0 to 4, carrying out said reaction at a temperature higher than a temperature such that it leads to the formation of C(O)FX2.

Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

Abstract: Processes for preparing amides of retinoic acid are disclosed. Intermediates useful in the preparation of amides of retinoic acid are also disclosed. In one version of the invention, fenretinide is produced via activation of retinoic acid (tretinoin) via its corresponding mixed anhydride or mixed carbonate followed by reaction of the activated intermediate with 4-aminophenol. Other amides of retinoic acid and isomers of retinoic acid, such as the 9-cis-form or 13-cis-form can also be made by this invention.

Abstract: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.

Abstract: The invention provides a method for efficiently producing an aromatic diamine derivative represented by formula (3) at high yield, the method including reacting an aromatic amide represented by formula (1) with an aromatic halide represented by formula (2): (wherein each of Ar, Ar1 and Ar2 represents a substituted or unsubstituted aryl group or heteroaryl group; Ar3 represents a substituted or unsubstituted arylene group or heteroarylene group; and X represents a halogen atom).

Abstract: The present invention relates to a process for the preparation of compounds of a 1,4-dialkyl-2,3-diol-1,4-butanedione by a catalytic aldol condensation between an alkyl glyoxal and an ?-hydroxy ketone.

Abstract: Process for preparing tricyclodecanedialdehyde by hydroformylation of dicyclopentadiene by means of a CO/H2 mixture at elevated temperature and under superatmospheric pressure in the presence of a rhodium catalyst which has not been modified by means of a ligand and is homogeneously dissolved in the hydroformylation medium, wherein the hydroformylation is carried out at a pressure of from 200 to 350 bar in at least two reaction zones, with a reaction temperature of from 80 to 120° C. being set in a first reaction zone and a reaction temperature of from 120 to 150° C. being set in a reaction zone following this reaction zone, with the proviso that the reaction temperature in the subsequent reaction zone is at least 5° C. higher than in the preceding reaction zone.

Abstract: A process for preparing aromatic bisphenols, wherein the method comprises reacting an aromatic hydroxy compound with an alkylating agent having a functionality of two in the presence of a catalyst system. The catalyst system used for the process is selected from the group consisting of a heteropolyacid compound, a clay, a functionalized metal oxide catalyst and combinations of the foregoing.

Abstract: The present invention is directed to asymmetric chiral labeled glycerols including at least one chiral atom, from one to two 13C atoms and from zero to four deuterium atoms bonded directly to a carbon atom, e.g., (2S) [1,2-13C2]glycerol and (2R) [1,2-13C2]glycerol, and to the use of such chiral glycerols in the preparation of labeled amino acids.

Abstract: The present invention relates to a method for producing a water-soluble fluorine-containing vinyl ether which comprises subjecting a fluorine-containing 2-alkoxypropionic acid derivative represented by the following general formula (I): (wherein A represents —OM1 or —OM21/2, and M1 represents an alkali metal and M2 represents an alkaline earth metal; X represents a halogen atom; Y1 and Y2 are the same or different and each represents a fluorine atom, a chlorine atom, a perfluoroalkyl group or a fluorochloroalkyl group; n represents an integer of 0 to 3, and n of Y1s may be the same or different; m represents an integer of 1 to 5, and m of Y2s are the same or different; and Z represents a hydrophilic group) to thermal decomposition at a temperature of not lower than 50° C. but lower than 170° C.

Abstract: A process for producing para-xylene by the selective methylation of toluene comprising contacting a reactant mixture comprising toluene, methanol and added water, with an oxide modified ZSM-5 zeolite catalyst in a flow reactor in conditions selected to limit coke formation on the catalyst and at a contact time, between reactant mixture and catalyst, of less than 1 second.